The Class II Tumor Suppressor Masping: From Bench to Bedside

Brain tumor headaches: from bedside to bench.

Although most people who have headache pain do not present with an underlying mass lesion, a large number of patients with brain tumors do report headache (as many as 60% in our institution). The problem for clinicians is that the tumor-headache association is not universal, as evidenced by anecdotal reports of patients with large tumors and increased intracranial pressure, but a complete absen...

Dendritic Cell Tumor Fusions from the Bench to the Bedside

From bench to bedside

Because the microcirculation has emerged as an important reanimation target, appropriate methods to monitor the microcirculatory function are crucial. Several teams have now succeeded in crossing this bridge from bench to bedside, but the choice of the tissues of interest remains a debate. The potential accessible vascular beds that doctors could use in reanimation strategies and the relationsh...

From Bench to Bedside

Since the initial experiments nearly a decade ago, remarkable progress has been made in the field of vascular gene transfer, and trials with human subjects already are under way. The potential of vascular wall gene transfer as therapy for various vascular diseases is considerable.1,2 The purpose of this review is 2-fold: (1) to delineate the methods and principles underlying vascular gene trans...

Tumor-tailored treatment of colorectal cancer: from bench to bedside?

Background A broad variety of systemic treatment options are available for non-resectable colorectal cancer in UICC stage IV disease. Depending on age, comorbidity, the possibility of a secondary resection, the personal experience with specific drug combinations, and national guidelines physicians choose a treatment option. At present, only Ki-ras status is determined as an individual biologica...